Catalent Inc.

14 Schoolhouse Road
NJ 08873 Somerset
US

Contact WebSite

Article

GenSight Biologics to Partner with Catalent on Gene Therapy Candidate
02.07.2025 • News

GenSight Biologics to Partner with Catalent on Gene Therapy Candidate

GenSight Biologics recently announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ, the Company’s gene therapy candidate product to CDMO Catalent.

Novo Holdings to Acquire Catalent for $16.5 Billion
08.02.2024 • News

Novo Holdings to Acquire Catalent for $16.5 Billion

Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said that Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.